# Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Source: https://onco.cc/trials/nct07175220/  
OnCo record `nct07175220` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-A2102, Retlirafusp alfa in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects is a phase 2 interventional study registered as NCT07175220 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2025-10-09 and due to reach its primary completion in 2028-10. Interventions recorded: SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701. Conditions listed: Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07175220
- Phase: 2
- Setting: A Multicenter, Open Label Phase II Clinical Study on the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination With Other Anti-tumor Treatments in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07175220: https://clinicaltrials.gov/study/NCT07175220

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07175220.json